Clinical Trial Update: T-DM1 Combined With CDK4/6 Inhibitor Ribociclib [Phase 2]

View source ↗

Summary

A Phase 2 clinical trial is evaluating the combination of T-DM1 (ado-trastuzumab emtansine) with the CDK4/6 inhibitor ribociclib for HER2-positive advanced brea…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Breast Cancer

Drugs mentioned

• KISQALI (ribociclib)
• Kadcyla (ado-trastuzumab emtansine)

Snippet

Sponsor: Zheng Yabing | Conditions: HER2-positive Advanced Breast Cancer | Phase 2 | Status: ENROLLING_BY_INVITATION